fda compounding glp-1 warning letters october 2025 Congress Introduces SAFE Drugs Act of 2025, Expanding Oversight of Compounded Drugs and Telehealth Providers Pharmaceutical Advertising Regulations

The metabolic rate of GLP-1R KO mice was significantly slower than that of WT mice (p=0.0345, WT mice 0.023350.057mM/min, GLP-1R KO mice 0.019980.07mM/min)

87% reduced carb cravings

Limited data are available on the risk of pancreatic adverse events among people with obesity or type 2 diabetes mellitus (T2DM) initiating glucagon-like peptide-1 receptor agonist (GLP-1 RA)

Program Page

GLP-1 Receptor Agonists and Aspiration Risk: From Universal Holding to Risk-Based Perioperative Management Review Abstract Purpose The rapid adoption ofglucagon-like peptide-1 receptor agonists (GLP-1 RAs)anddual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonistshas transformed the management of type 2 diabetes mellitus and obesity